Cannabidiol (CBD)

Contentus

• Verisimile est effective ...
• Effectiveness rate ut quod est insufficiens ...
• & Cautiones admonitio specialis;

Cannabis sativa Cannabidiol est eget per plant, et stuppea vel quae Marijuana. Super LXXX oeconomiae, quae cannabinoids: Cannabis sativa sunt realiter idem per plant. Dum gamma-IX-tetrahydrocannabinol (THC) Maior est agens ingrediens in Marijuana, cannabidiol adeptus est et amplum de canabo, quod continet ipsum tantum parvum copia THC.

Praeteritis MMXVIII firme Bill fecit illud, et cannabis legum cannabis vendere products in US sed non intelliguntur omnes qui legum cannabis tot propriae cannabidiol products sunt. Cum cannabidiol novum medicamento scitu iucunda est, ea includi in cibis et legibus potest non esse puritate alimentorum supplemento. Item, cannabidiol non includitur in products venales apud alium curandum necessitudinibus habuisse potiora. Cannabidiol modo includi poterit in "medicamine 'products et tantum continet minus quam 0.3% THC. At etiam sunt intitulatum ut puritate alimentorum supplemento in foro products quod continent cannabidiol. Cannabidiol products moles continebat quod in his non est relatus verius semper in uber titulus.

Cannabidiol est plerumque adsuesco assuesco pro captione inordinatio (comitiali). Et quia usus est, anxietatem, dolor, qui dicitur dystonia inordinatio in musculus, Parkinson morbum Crohn, et multa alia condiciones, sed est scientific indicio suscipere huiusmodi bonorum usibus libera.

Naturalis conficiendi medicamenta Comprehensive Database rates fundatur super efficaciam scientific hoc quod ex scale: Effectiva, minime efficax, efficax Forsitan, Fortasse senserunt esse, minime Ineffective, Ineffective et Rate est quaedam feruntur.

Et efficaciam ratings CANNABIDIOL (CBD) ita se habet:

Verisimile est effective ...

• Captione inordinatio (comitiali). A specifica cannabidiol productum (Epidiolex GG Pharma) invasiones in adultis et filii sunt ostensum ad redigendum in variis conditionibus, quae sunt coniunctum cum caducis. Hoc productum est causa rapinae et huiusmodi praescriptio medicamento pro somes per Dravet syndrome, Levinius-Gastaut syndrome, aut tuberosa universa duros nequeunt movere lumbos. Quod etiam ostensum ad redigendum invasiones in populum, cum Sturye Weber syndrome, lingua sed torpet infectio-related morbo comitiali syndrome (IGNES), et propria causa quod caducum encephalopathy perturbationes geneticae. Quia probatus est sed suus 'non typus of alio respicientes velut caducis. Hoc productum est anti-captio conventional utilitas plerumque cum capta tandem coniunctim afficient vniuersa. Quidam products cannabidiol quæ fiunt in a Lab sunt quoque studium desit tale ad epilepsiam. Sed limited investigationis est: et nemo ex his products fuerint probatus est praescriptio medicinae.

Effectiveness rate ut quod est insufficiens ...

• A genus alvum inflammatory morbus (Crohn). Investigationis ostendit quod non redigendum mane taking cannabidiol morbo actio in adultis cum Crohn.
• DIABETES. Mane investigationis ostendit quod non taking cannabidiol amplio sanguinem GLYCOSA imperium type II diabetes in adultis.
• A motus inordinatio insignitur per involuntarium musculus contractionem (dystonia). Incertum est si hoc expediat cannabidiol dystonia.
• An ex doctrina defectus originalis condicionis notatum (X fragile- syndrome). Anxietatem ingerit quod investigatio mane refert et redigendum cannabidiol gel ut amplio morum syndrome in infantes X fragili.
• A conditione, in qua petit laceratque corpus traducere (versus inserere, aut morbo, exercitum GVHD). Morbus est, exercitum versus Virus-DIFFICULTAS post medullae ossium PLANTO, quod potest fieri. Research dicit quod si accipiatur primo inuenit cannabidiol cotidie VII diebus ante incipiens medullae ossium PLANTO et duraturam per XXX dies post PLANTO tempus prorogari potest develop accipit homo in GVHD.
• Hereditario quodam cerebri inordinatio motus, motus et cogitandi (Cambridge University morbus). Investigationis ostendit diluculo symptoms amplio non dicit quod si accipiatur cannabidiol cotidie Synodi morbo.
• Multa duros nequeunt movere lumbos (MS). Mane investigationis insinuat quod sub lingua usus aspergine cannabidiol ut amplio musculus dolor, et emissiones habent sunt in populo MS.
• Effugia heroine, morphine aliaque medicamenta opioid. Investigationis ostendit quod mane acceptis cannabidiol III dies ad redigendum ut heroin usum inordinationem appetitus, et uariis difficultatibus uiae est in populo.
• Parkinson morbus. Investigationis ostendit quod mane ut cannabidiol anxietatem et redigendum symptoms in psychotici populus cum Parkinson morbo.
• SCHIZOPHRENIA. Diluculo symptoms amplio cannabidiol taking research insinuat quod populus cum wellbeing in SCHIZOPHRENIA.
• Quitting fumigans. Mane una sabbatorum investigationis insinuat quod inflatis haurire cannabidiol cum an inhaler ad redigendum ut numerus cigarettes fumabat per smokers ad quieti conatur.
• A genus anxietatem notata metu ab aliquo vel omni in sociali occasus (anxietatem socialis inordinatio). Investigationis ostendit quod mane cannabidiol ut amplio anxietatem inordinatio in populo huic. Sed si illud obscurum adjuvat in publicum redigendum anxietatem loqui.
• A maxilla iuncturam et musculus coetus afficit, quod de dolore conditionibus (vel perturbationes TMD temporomandibularis). Investigationis ostendit quod mane applicante cannabidiol continet oleum in ut cutis ad redigendum dolor TMD est in populo.
• Nervi dampnum in manus et pedes (periphericis neuropathia).
• bipolar inordinatio.
• Insomnia.
• aliis conditionibus.

Quod magis necesse est ut ad efficaciam rate de cannabidiol propter illos usus.

Cannabidiol effectus in cerebrum non habet. Ad tertium causae, quia sunt effectus est non manifestum. Sed ne cannabidiol videtur naufragii de quodam eget dolor in cerebrum, mente et mentis munus. Prohibendo naufragii huius eget elit et incrementum in sanguine suo ad redigendum videtur psychotici signa consociata cum conditionibus, ut SCHIZOPHRENIA. Etiam Cannabidiol angustos quidam ex effectis psychotropica gamma-IX-tetrahydrocannabinol (THC). Etiam metus dolor cannabidiol reduci videtur.

Cum sublatus ab oris: Quod Cannabidiol POTEST FIERI ARMARIUM cum sublatus a mare iniecto in ore et lingua tur. Usque ad CCC mg quotidie gustatu de Cannabidiol in capta sunt ab secure ore usque ad VI mensibus. 1200-1500 mg quotidie gustatu de superiore sumpta sunt ab secure ore enim ad IV weeks. A cannabidiol cheap uber (Epidiolex) ut probatus est in capta ab ore usque ad XXV bibitur mg / kg cotidie. Sacra, quae sub lingua sunt Cannabidiol applicantur ad usus est in gustatu de 2.5 ad II weeks mg forma.

Cannabidiol ex parte effectus includit ore sicco Quidam nuntiata, humilis sanguinem pressura, lux headedness potibus et dantes symbola. Signa etiam iecur injuriam non relata in quibusdam aegris, sed hoc est minus commune.

Cum applicantur ad cutem, Non satis certa notitia est tutum scire si est aut quid latus effectus cannabidiol esset.

& Cautiones admonitio specialis;

Graviditate ac loricam pascens: Quod Cannabidiol POTEST FIERI PERICULOSUS ut si vos es gravida aut pectus pascens. Cannabidiol products potest contaminari cum ceteris nocivis, ut sit in embryonis seu infantis. Tuto manere, ne usu.

liberi: A cannabidiol cheap uber (Epidiolex) est, POTEST FIERI ARMARIUM cum bibitur in capta ab ore usque ad XXV mg / kg cotidie. Hoc productum est aliqua probatus est usus liberi I anno aetatis et senior.

iecoris morbus: Populus iecoris morbo, ut cum necesse est ut gustatu de minus cannabidiol comparari sanus aegris.

Parkinson morbus: Quidam research insinuat quod si accipiatur primo altum gustatu de cannabidiol ut faceret musculus motus tremoribus et in peius quidam populus cum Parkinson morbo.

moderatus

Videte, hoc compositum.

Brivaracetam (Briviact)

Brivaracetam fractus corpore mutatur. Ad velocitatem corporis minuerit Cannabidiol brivaracetam metus. Hæc ordinis brivaracetam ut crescat in corpore.

Carbamazepine (Tegretol)

Carbamazepine fractus corpore mutatur. Ad velocitatem corporis minuerit Cannabidiol carbamazepine metus. Et hoc augmentum corporis augmentum gradus carbamazepine effectus.

Clobazam (Onfi)

Extrita iecur Clobazam mutatur. Citius descendere Clobazam minuerit Cannabidiol iecoris frangit. Hoc auget effectum Clobazam parte effectus.

Eslicarbazepine (Aptiom)

Eslicarbazepine fractus corpore mutatur. Ad velocitatem corporis minuerit Cannabidiol eslicarbazepine metus. Crescere posset in corpore parum eslicarbazepine gradus.

Everolimus (Zostress)

Everolimus fractus corpore mutatur. Ad velocitatem corporis minuerit Cannabidiol everolimus metus. Hæc ordinis everolimus ut crescat in corpore.

Calcium

Tollens altius bibitur de Lithium levels cannabidiol ut crescat. Hoc potest ad augendam periculo Lithium toxicity.

Mutata in medicina iecoris (1A1 cytochrome P450 (CYP1A1) subiectae)

Extrita medicamenta mutatae iecur. Medicamenta aliqua celerem minuerit Cannabidiol iecoris frangit. Definiunt, cum per medicamenta quae destructae cannabidiol iecore augeret effectus medicamenta parte effectus. Antequam uti cannabidiol, Disputatio vestris curis provisor si tibi est aliquo accipere medications, qui sunt mutata in iecur.

Quidam medications mutata in includit iecoris chlorzoxazone (Lorzone) et theophylline (Theo-Dur, alii).

Mutata in medicina iecoris (1A2 cytochrome P450 (CYP1A2) subiectae)

Extrita medicamenta mutatae iecur. Medicamenta aliqua celerem minuerit Cannabidiol iecoris frangit. Definiunt, cum per medicamenta quae destructae cannabidiol iecore augeret effectus medicamenta parte effectus. Antequam uti cannabidiol, Disputatio vestris curis provisor si tibi est aliquo accipere medications, qui sunt mutata in iecur.

Quidam medications mutata in includit iecoris amitriptyline (Elavil), haloperidol (Haldol), ondansetron (Zofran), propranolol (Imovax), theophylline (Theo-Dur, alii), verapamil (Calan, Isoptin, alii), et aliis.

Mutata in medicina iecoris (cytochrome P450 1B1 (CYP1B1) subiectae)

Extrita medicamenta mutatae iecur. Medicamenta aliqua celerem minuerit Cannabidiol iecoris frangit. Definiunt, cum per medicamenta quae destructae cannabidiol iecore augeret effectus medicamenta parte effectus. Antequam uti cannabidiol, Disputatio vestris curis provisor si tibi est aliquo accipere medications, qui sunt mutata in iecur.

Quidam medications mutata in iecur includit theophylline (Theo-Dur, alii), omeprazole (Prilosec, Omesec), clozapine (Clozaril, FazaClo), progesterone (Prometrium, alii), lansoprazole (Prevacid), flutamide (Eulexin), oxaliplatin (Eloxatin ), erlotinib (Tarceva), and Julius.

Mutata in medicina iecoris (2A6 cytochrome P450 (CYP2A6) subiectae)

Extrita medicamenta mutatae iecur. Medicamenta aliqua celerem minuerit Cannabidiol iecoris frangit. Definiunt, cum per medicamenta quae destructae cannabidiol iecore augeret effectus medicamenta parte effectus. Antequam uti cannabidiol, Disputatio vestris curis provisor si tibi est aliquo accipere medications, qui sunt mutata in iecur.

Quidam medications mutata in includit iecoris consectetuer, chlormethiazole (Heminevrin), Alcaloide, methoxyflurane (Penthrox), halothane (Fluothane) acidum valproicum (Depacon), disulfiram (Antabuse), et aliis.

Mutata in medicina iecoris (cytochrome P450 2B6 (CYP2B6) subiectae)

Extrita medicamenta mutatae iecur. Medicamenta aliqua celerem minuerit Cannabidiol iecoris frangit. Definiunt, cum per medicamenta quae destructae cannabidiol iecore augeret effectus medicamenta parte effectus. Antequam uti cannabidiol, Disputatio vestris curis provisor si tibi est aliquo accipere medications, qui sunt mutata in iecur.

Quidam medications mutata in includit iecoris ketamine (Ketalar), phenobarbital, orphenadrine (Norflex), secobarbital (Seconal), et dexamethasone (decadron).

Mutata in medicina iecoris (cytochrome P450 2C19 (CYP2C19) subiectae)

Extrita medicamenta mutatae iecur. Medicamenta aliqua celerem minuerit Cannabidiol iecoris frangit. Definiunt, cum per medicamenta quae destructae cannabidiol iecore augeret effectus medicamenta parte effectus. Antequam uti cannabidiol, Disputatio vestris curis provisor si tibi est aliquo accipere medications, qui sunt mutata in iecur.

Quidam medications, comprehendo inhibitors vertit ad sentinam protón includit iecoris omeprazole (Prilosec), lansoprazole (Prevacid), et pantoprazole (Protonix); valium (valium); cialis (Ultram); nelfinavir (Viracept); et alii.

Mutata in medicina iecoris (cytochrome P450 2C8 (CYP2C8) subiectae)

Extrita medicamenta mutatae iecur. Medicamenta aliqua celerem minuerit Cannabidiol iecoris frangit. Definiunt, cum per medicamenta quae destructae cannabidiol iecore augeret effectus medicamenta parte effectus. Antequam uti cannabidiol, Disputatio vestris curis provisor si tibi est aliquo accipere medications, qui sunt mutata in iecur.
Quidam medications mutata in includit iecoris amiodarone (Cordarone), carbamazepine (Tegretol), chloroquine (Aralen), diclofenac (Voltaren), paclitaxel (Spermatophyta), repaglinide (Prandin) et aliis.

Mutata in medicina iecoris (cytochrome P450 2C9 (CYP2C9) subiectae)

Extrita medicamenta mutatae iecur. Medicamenta aliqua celerem minuerit Cannabidiol iecoris frangit. Definiunt, cum per medicamenta quae destructae cannabidiol iecore augeret effectus medicamenta parte effectus. Antequam uti cannabidiol, Disputatio vestris curis provisor si tibi est aliquo accipere medications, qui sunt mutata in iecur.

Quidam medications mutata in includit iecoris nonsteroidal anti-inflammatione medicinae (NSAIDs) ut diclofenac (Cataflam, Voltaren), ibuprofen (Motrin), meloxicam (Mobic), piroxicam (feldene), et celecoxib (Celebrex); amitriptyline (Elavil); warfarin (Coumadin); glipizide (Glucotrol); losartan (Cozaar); et alii.

Mutata in medicina iecoris (cytochrome P450 2d6 (CYP2D6) subiectae)

Extrita medicamenta mutatae iecur. Medicamenta aliqua celerem minuerit Cannabidiol iecoris frangit. Definiunt, cum per medicamenta quae destructae cannabidiol iecore augeret effectus medicamenta parte effectus. Antequam uti cannabidiol, Disputatio vestris curis provisor si tibi est aliquo accipere medications, qui sunt mutata in iecur.

Quidam medications mutata in iecur includit amitriptyline (Elavil), CODEINUM, desipramine (Norpramin), flecainide (Tambocor), haloperidol (Haldol), imipramine (Tofranil), metoprolol (Lopressor, Toprol XL): ondansetron (Zofran), paroxetine (Paxil ), risperidone (Risperdal), dogs (Ultram), venlafaxine (Effexor), et aliis.

Mutata in medicina iecoris (3A4 cytochrome P450 (CYP3A4) subiectae)

Extrita medicamenta mutatae iecur. Medicamenta aliqua celerem minuerit Cannabidiol iecoris frangit. Definiunt, cum per medicamenta quae destructae cannabidiol iecore augeret effectus medicamenta parte effectus. Antequam uti cannabidiol, Disputatio vestris curis provisor si tibi est aliquo accipere medications, qui sunt mutata in iecur.

Quidam medications mutata in iecur includit valium (Mg), amlodipine (Norvasc), clarithromycin (Biaxin), cyclosporine (Sandimmune), atenolol, lovastatin (Mevacor), ketoconazole (Nizoral), itraconazole (Sporanox), fexofenadine (Allegra), triazolam (Halcion), verapamil (Calan, Isoptin) et multis aliis.

Mutata in medicina iecoris (3A5 cytochrome P450 (CYP3A5) subiectae)

Extrita medicamenta mutatae iecur. Medicamenta aliqua celerem minuerit Cannabidiol iecoris frangit. Definiunt, cum per medicamenta quae destructae cannabidiol iecore augeret effectus medicamenta parte effectus. Antequam uti cannabidiol, Disputatio vestris curis provisor si tibi est aliquo accipere medications, qui sunt mutata in iecur.

Quidam medications mutata in testosterone includit iecoris, progesterone (Endometrin, Prometrium), nifedipine (Adalat C, L Procardia), cyclosporine (Sandimmune), et aliis.

Mutata in medicina iecoris (Glucuronidated medicinae VI)

Extrita medicamenta mutatae iecur. Medicamenta aliqua celerem minuerit Cannabidiol iecoris frangit. Assumptis secum medicamenta quae destructae cannabidiol iecore excrescere effectus medicamenta ex parte effectus.
Quidam ex his medications mutata in includit iecoris acetaminophen (Tylenol, alii) et oxazepam (Serax), haloperidol (Haldol), lamotrigine (Lamictal), MORPHINUM (MS Contin, Roxanol), zidovudine (AZT, Retrovir), et aliis.

Ie ad naufragii de aliis medications, qui medicamentum ex iecur (cytochrome P450 2C19 (CYP2C19) inhibitors)

Dissipatus Cannabidiol iecore. Citius descendere quam minuerit medicamenta cannabidiol iecoris frangit. Inito cum ea medicamenta cannabidiol augeret effectus cannabidiol parte effectus.
Quidam medications qui minuerit cannabidiol naufragii in in includit iecoris cimetidine (Tagamet), Fluvoxamine (Luvox), omeprazole (Prilosec); ticlopidine (Ticlid), topiramate (Topamax), et aliis.

Ie ad naufragii de aliis medications, qui sunt in medicamentum iecoris (3A4 cytochrome P450 (CYP3A4) inhibitors)

Dissipatus Cannabidiol iecore. Citius descendere quam minuerit medicamenta cannabidiol iecoris frangit. Inito cum ea medicamenta cannabidiol augeret effectus cannabidiol parte effectus.
Quidam medications qui minuerit, quam cito iecur deiecerit cannabidiol includit amiodarone (Cordarone), clarithromycin (Biaxin), Diltiazem (Cardizem), atenolol (E-mycin, Erythrocin), indinavir (Crixivan), ritonavir (Norvir), saquinavir (Fortovase , Invirase), et multis aliis.

Medicamentum ex aliis medications, qui de naufragii incremento iecur (3A4 cytochrome P450 (CYP3A4) Inducers)

Dissipatus Cannabidiol iecore. Et cito excrescere medicamenta cannabidiol iecoris frangit. Inito cum ea medicamenta cannabidiol minuerit cannabidiol effectus.
Quidam ex his includit medicinae carbamazepine (Tegretol), phenobarbital, phenytoin (Dilantin), rifampin, rifabutin (Mycobutin), et aliis.

Medicamentum ex naufragii in disputando habentia medicamentum ab aliis iecoris (cytochrome P450 2C19 (CYP2C19) Inducers)

Dissipatus Cannabidiol iecore. Et cito excrescere medicamenta cannabidiol iecoris frangit. Inito cum ea medicamenta cannabidiol minuerit cannabidiol effectus.
Quidam medications qui de naufragii, ut proventus in cannabidiol includit iecoris carbamazepine (Tegretol) valium (deltasone), et rifampin (Rifadin, Rimactane).

Methadone (Dolophine)

Dissipatus methadone iecore. Citius descendere methadone minuerit Cannabidiol iecoris frangit. Cum augeret methadone cannabidiol accipiendo effectum methadone parte effectus.

Rufinamide (Banzel)

Rufinamide fractus corpore mutatur. Ad velocitatem corporis minuerit Cannabidiol rufinamide metus. Crescere posset in corpore parum rufinamide gradus.

Leniendo medicamentum (CNS nervosa)

Sopitum somno Cannabidiol consecraret. Causa quod rememdium mobilitatem torpor sedativi dicuntur. Inito cum leniendo cannabidiol medicamenta nimium faciat somno.

Quidam medications includit benzodiazepines leniendo, pentobarbital (Nembutal), phenobarbital (luminal), secobarbital (Seconal), thiopental (Pentothal), Fentanyl (Duragesic, Sublimaze), MORPHINUM, propofol (Diprivan), et aliis.

Sirolimus (Rapamune)

Sirolimus fractus corpore mutatur. Ad velocitatem corporis minuerit Cannabidiol Sirolimus metus. Hæc ordinis Sirolimus ut crescat in corpore.

Stiripentol (Diacomit)

Stiripentol fractus corpore mutatur. Ad velocitatem corporis minuerit Cannabidiol stiripentol metus. Et hoc augmentum corporis augmentum gradus stiripentol effectus.

Tacrolimus (prograf)

Tacrolimus fractus corpore mutatur. Ad velocitatem corporis minuerit Cannabidiol tacrolimus metus. Hæc ordinis tacrolimus ut crescat in corpore.

Topiramate (Tompamax)

Topiramate fractus corpore mutatur. Ad velocitatem corporis minuerit Cannabidiol topiramate metus. Crescere posset in corpore parum topiramate gradus.

valproate

Acidum valproicum potest facere iecoris injuria. Acidum valproicum ne forte ex iecoris cum cannabidiol accipiens injuria proventus. Cannabidiol et / vel acidum valproicum totis viribus opus est redargui, non opus est ut potionis reduci.

warfarin

Ut warfarin Cannabidiol auget gradibus, quae possit augere periculo pro sanguinem. Cannabidiol et / vel warfarin totis viribus opus est redargui, non opus est ut potionis reduci.

Zonisamide

Zonisamide fractus corpore mutatur. Ad velocitatem corporis minuerit Cannabidiol zonisamide metus. Crescere posset in corpore parum zonisamide gradus.

Ac cum supplemento herbis proprietatibus leniendo

Cannabidiol potest somnus imminens mobilitatem torpor aut faciam. Cum aliis herbis uti Supplementis habentium eandem nimium faciat somno. Quidam supplements includunt et ab his herbis, calamus aromaticus, California papaver, catnip, ASSULTIM, Jamaican dogwood, potionis kava: Dominus tryptophan, melatonin, ac sapiens idem et diversum Sancti Ioannis struthio, saxifragium, pileolum et aliis.

Alcohol (Ethanol)

Vocatus est cannabidiol cannabidiol accepta moles absorberi corporis auget. Hoc auget effectum cannabidiol parte effectus.

Adipes et adipem contineat cibis

Et tollens panem cannabidiol saltem aliquod sublime adipem pinguium cannabidiol maiorem mensuram corporis quod absorbetur. Hoc auget effectum cannabidiol parte effectus.

lac

Accepta moles cannabidiol cannabidiol lacte addat corpori intenta est. Hoc auget effectum cannabidiol parte effectus.

Et hoc genus institutorum continentur in portione medicatur altius sunt investigatae;

PUBERES

Per os:

• enim miser morbo comitiali: A cannabidiol cheap uber (Epidiolex) usus est. Et Levinius-Gastaut syndrome et commendatae incipiens dose pro syndrome est Dravet 2.5 mg / kg bis cotidie (V mg / kg / die). Una post septimana dose potest augeri ad V mg / kg bis cotidie (X mg / kg / die). Respondeo dicendum quod ad hoc quod homo si non terminantur, est maxime suadetur X mg / kg bis cotidie (XX mg / kg / die). Et incipiens suadetur dose est universa tuberosa duros nequeunt movere lumbos 2.5 mg / kg bis cotidie (V mg / kg / die). Potest crevit felis intervalla necessitate ad maximum 12.5 mg / kg quotidie bis (XXV mg / kg / die). Non est scientific indicio, quod fortis nonprescription cannabidiol products sunt utile putant ad comitialibus.

LIBERI

Per os:

• enim miser morbo comitiali: A cannabidiol cheap uber (Epidiolex) usus est. Et Levinius-Gastaut syndrome et commendatae incipiens dose pro syndrome est Dravet 2.5 mg / kg bis cotidie (V mg / kg / die). Una post septimana dose potest augeri ad V mg / kg bis cotidie (X mg / kg / die). Respondeo dicendum quod ad hoc quod homo si non terminantur, est maxime suadetur X mg / kg bis cotidie (XX mg / kg / die). Et incipiens suadetur dose est universa tuberosa duros nequeunt movere lumbos 2.5 mg / kg bis cotidie (V mg / kg / die). Potest crevit felis intervalla necessitate ad maximum 12.5 mg / kg quotidie bis (XXV mg / kg / die). Non est scientific indicio, quod fortis nonprescription cannabidiol products sunt utile putant ad comitialibus.

II - [(1R, 6R) Methyl-3-VI-en huius, I-II-II-en-I-y-, ylcyclohex] -5-pentylbenzene-1,3-diol, CBD.

Ut plures nuntios circa quam est articulus est scriptum, placet videre Naturalis conficiendi medicamenta Comprehensive Database methodorum sive inventarum.

1. A. Singh, Dillon B, Tatum ducla eft KC De Tessenderlo: Canticum Bonthius. -Medicamento et medicamento interactiones inter Cannabidiol Lithium. Puer Neurol appellavere. MMXX: VII: 2329048X20947896. View abstracto.
2. Izgelov D, E Tullius Cicero, Barasch D, A Regev, Domb AJ, A. Cornelius Pharmacokinetic inquisitio de synthetica cannabidiol formulae sunt reperiendae, in oris sanus voluntariorum fuit. J Biopharm pharm. MMXX, CLIV, 108-115. View abstracto.
3. Gurley BJ, Murphy TP Allelúja, Gul W: O Walker, ElSohly M. Content petit versus Label Cannabidiol (CBD) Products -Containing Adepta a Commercial Outlet a Mississippi ad rem publicam. Victu J v. MMXX: XVII: 599-607. View abstracto.
4. McGuire P: P Venice: S. Cubala, et al. Cannabidiol (CBD) as an Adjunctiva Therapy in SCHIZOPHRENIA: A multicenter Randomized dispensata Trial.Am J Psychiatry. MMXVIII: CLXXV, 225-231. View abstracto.
5. J. Cortopassi Warfarin dose, post temperatio requiritur cannabidiol titratione voluptate et luxuria. Salutem J am pharm syst. MMXX, LXXVII, 1846-1851. View abstracto.
6. Tabula Bloomfield, Viridis SF, Hindocha C, et al. Et anguli cannabidiol effectus cerebri ad relatione ad memoriam ejus, et sanguis: An arteriarum nent labeling RMN studium. J Psychopharmacol. MMXX, XXXIV, 981-989. View abstracto.
7. Gaudium et Wang, Bourne DWA, Klawitter J; et al. Cannabis Rich dispositio oris Cannabidiol-Extracts in filii cum comitialibus. Pharmacokinet Clin. 2020. View abstracto.
8. Taylor Dominus Davius ​​Crockett J, Tayo B, D Checketts, Sommerville subtractionem, aut C. Abrupt cannabidiol (CBD): A randomized iudicium. Comitialibus Behav. MMXX: CIV Romani (A) (CVI)CMXXXVIII. View abstracto.
9. McNamara NA, Dang LT, Sturza J; et al. Acidum valproicum in pediatric aegros et concurrentes cannabidiol in thrombocytopenia. Epilepsia. 2020. View abstracto.
10. T Rianprakaisang, Gerona R: Nabu KG. Commercial cannabidiol contaminari oleum de Saccharum Cannabinoid FUBINACA AB, datum est a pediatric patientes estote. Clin Toxicol (Phi). MMXX: LVIII: 215-216. View abstracto.
11. Cicero G Davius ​​Crockett J, Blakey G, K Sommerville Phase I: Aperi-Label: explora Pharmacokinetic Tentatio ut possibile-medicamentis Drug Interactions Inter Clobazam, Stiripentol aut valproate in sanus subditis et Cannabidiol. Clin Pharmacol medicamentis Apuleius. MMXIX, VIII, 1009-1031. View abstracto.
12. Ego Miller, Scheffer III, Gunning B, et al. Phosphate Vndique effectum conflictus, nos Adjunctiva oris Cannabidiol Victoria Musicæ In Frequency in iure apud insanos comprimere Syndrome Dravet: A randomized Volume iudicium. JAMA Neurol. MMXX, LXXVII, 613-621. View abstracto.
13. Lattanzi S, David E, Striano P, et al. Cannabidiol penitus efficaciae nulliusque Clobazam status: systematicam review A-analysis et meta. Epilepsia. MMXX: LXI: 1090-1098. View abstracto.
14. Hobbes | JM: See English Vazquez, Remijan ND, et al. Farmacocinética iudicium de anti-inflammatione potentiale et acutus ex duabus oris cannabidiol praeparassent sanus adultis. Res Phytother. MMXX, XXXIV, 1696-1703. View abstracto.
15. Ebrahimi Fakhari D-Agricolae tangentibus KD, Theodorus C, D Malotia Krueger, Johann DN. Cannabidiol elevat naturam demonstrant machinariam target campester in aegroti et inhibitor Rapamycin in complexu Morbus MEMORIOLA. Pediatr Neurol. MMXX, CV, 59-61. View abstracto.
16. de Carvalho Reis R: Latin draconem, da Silva Lopes Domino, de Melo Mendetis Theologumenon CM, Shu-E lacu Seng laqueo et adversa res Efficaciam Profile of cannabidiol et medicinam sustinere cannabis quia repugnans curatio comitialibus: Nomina Systematica recensionem et meta-analysis. Comitialibus Behav. MMXX, CII: (CVI)DCXXXV. View abstracto.
17. Darweesh ES, Khamis CA, El-de effectus Elimat T. cannabidiol in Farmacocinética in carbamazepine ab mures inclusi essent. Arcus Naunyn Schmiedebergs Pharmacol. 2020. View abstracto.
18. Davius ​​Crockett J, Critchley D, B Tayo, Berwaerts J: Cicero tempus A G. I, randomized, pharmacokinetic iudicium de diversis effectus in scriptis prandium, totum lac et cannabidiol Vocatus in in nulla salus, et sanus subditis. Epilepsia. MMXX: LXI: 267-277. View abstracto.
19. Cheinei E, D. D, viridis A, et al. Cannabidiol ex adversa effectus: systematicam review quod analysis of meta-randomized Volume iudiciis. Neuropsychopharmacology. 2020. View abstracto.
20. Ben-E Manahem, Gunning B, Cabrera recta CM Arenis, et al. Phase II A randomized iudicium, ut investigaret et exploraret potential pro Pharmacokinetic medicamentis vel medicamentis interactions cum Stiripentol deducta Cannabidiol in valproate cum aegris comitialibus. Potis Pharmaca. MMXX, XXXIV, 661-672. View abstracto.
21. Bass J: Marcus Reverendissimo ac Nobili Dom. Ex A Insecta Insecta a Cannabidiol Gummy. Cureus. MMXX: XII: e7688. View abstracto.
22. Messa di Gloria: AJ, M Grimaldi, J Axelrod, et Cannabidiol D. Male (-) Delta9-sunt tetrahydrocannabinol neuroprotective facilisis. Kessinger Publishing Acad Sci Phil MCMXCVIII A. U S; XCV, 8268-73. View abstracto.
23. Hacke ACM, Lima D, F de Costa Rica, et al. Scrutantium recipiunt antioxidant in actione [Delta] In Cannabis sativa cannabidiol -tetrahydrocannabinol et posui. Analyticum. MMXIX; CXLIV, 4952-4961. View abstracto.
24. Madden K, K Tanco, Bruera Amet C. Post insignes in Doctrina Novae Hierosolymae Inter Methadone medicamentis, medicamentis et Cannabidiol. Pediatrics. MMXX, e20193256. View abstracto.
25. Quod cum A. Hazekamp tribulationis CBD oleum. Cannabis cannabinoids med. Iun MMXVIII: I, 65-72.
26. Xu DH, Cullen D, M Tang, Fang V. Inter has formas, de Subsidio Symptomatic Bible Cannabidiol'oleum in periphericis neuropathia inferiorum partium. Pharm Biotechnol curr. Dec MMXIX View 1. abstracto.
27. M. de Faria, de Morais Fabricio D, V Tumas, et al. Effectus anguli cannabidiol in anxietatem et administrationis tremoribus adductus simulatus Public Speaking Test in aegris cum Parkinson scriptor morbus. J Psychopharmacol. Ian MMXX VII: 269881119895536. View abstracto.
28. Nitecka Buchta-A, Nowak, Wachol A, K Wachol, et al. Effectus Myorelaxant transdermal Cannabidiol aegroti, in Application et TMD: A randomized, Tentatio duplex caecus. Clin J Med. MMXIX Nov VI: VIII. pii: E1886. View abstracto.
29. Effectus curatio multiplex Cannabidiol anxiolytic Masataka tuarum N. et teenagers in Social Anxietas Morbositates. Psychol ante. MMXIX Nov VIII, X: MMCDLXVI. View abstracto.
30. Appianus Kusi-E: Petrus N, R Wilson, et al. Cannabidiol brevis-term effectus in curatio in ut socialis accentus responsio ad libitum orci in altus periculum of developing PSYCHOSIS. Psychopharmacology (Berl.) Ian 8 MMXX View abstracto.
31. Hussain SA Dlugos Song: Unio MR, Parikh N, O A, gradu Sankar R. Nova pharmaceutical cannabidiol quia curatio praefracti infantiles nervorum distentiones: A II-tempus multicenter studium. Comitialibus Behav. Ian MMXX, CII: (CVI)DCCCXXVI. View abstracto.
32. A. Klotz, Grob D, Hirsch M, B Metternich, Schulze Bonhage-A, et TOLERATIO operationes efficaciam Jacobs J. Nova et curatione medicamento Cannabidiol quia repugnans Comitialibus. Ante Neurol. Dec MMXIX X: X: MCCCXIII. View abstracto.
33. "VUL tecta eius et PLC Americae Subsidiary Biosciences Greenwich, Inc. adversum EPIDIOLEX® (cannabidiol) oralis solutio est perducta Descheduled et es non modesta substantia. ' Pharma VUL, VI Aprilis 2020. http://ir.gwpharm.com/node/11356/pdf. Aenean interdum accumsan luctus.
34. Wiemer Kruel-A, B Stiller, basi Cannabidiol Interacts C. Ne, queso, cum Everolimus Report a Morbus patientes in complexu MEMORIOLA. Neuropediatrics. 2019. View abstracto.
35. FDA Consumer Updates: Quid scire debes de Using Cannabis, Complectens et CBD, ie quando gravida aut ubere. S. V. Cibus et medicamentis Administration (FDA). Octobris 2019. Available at: https://www.fda.gov/consumers/consumer-updates/what-you-should-know-about-using-cannabis-including-cbd-when-pregnant-or-breastfeeding.
36. Taylor Dominus Davius ​​Crockett J, Tayo B, A G. pars I Cicero, dicens: Aperite-Label: Group-Psalter, Single-Insecta DE Farmacocinética et praesidia salutis Cannabidiol (CBD) Mitis ut in rebus severe hepatis medicis usui. J Clin Pharmacol. MMXIX, LIX, 1110-1119. View abstracto.
37. Szaflarski JP, id augue a K, Bebin affectibus animi, et al. Plasma cannabidiol altior gradus consociata cum hoc responso melius curatio cum a pharmaceutical gradu cannabidiol capcione delinquit. Comitialibus Behav. MMXIX, XCV, 131-136. View abstracto.
38. Pretzsch CM, Voinescu B; MA in fignis Borealibus, et al. Cannabidiol effectum (CBD) in adultis frequency actionem cerebri functiones conectividad placerat ac sine tumultu autism (ASD). J Psychopharmacol. MMXIX: 269881119858306. View abstracto.
39. Pretzsch CM, Freyberg A, B Voinescu, et al. Effectus in cerebrum excitatio et inhibitionis de cannabidiol systems; placebo-sobrie iudicium in pondere RMN a randomized una cum spectroscopium adultis sine spectro inordinationem autism. Neuropsychopharmacology. MMXIX: XLIV: 1398-1405. View abstracto.
40. A patriciis delecti, Versic Bratincevic, M, T Mijacika, et al. Aditus Examinatio in Latin for Oral Delivery Cannabidiol in sanus subditis: A randomized, Geminus-obcaecatis mentibus affulgeret, placebo-sobrie Farmacocinética Study. Ibi Adv. 2019. View abstracto.
41. R. Martin, Gaston TE, M Thompson, et al. Cognitiva functio munerum post longum-term treatment cannabidiol usu in repugnant morbus caducus et adultis. Comitialibus Behav. MMXIX: XCVII: 105-110. View abstracto.
42. Leino AD, Emoto C, T Fukuda, Privitera M, Vinks dictum est, Alloway Christum Dominum nostrum. Illa Sit Idoneus amet medicamento-medicamento actionem mutuam significant et cannabidiol tacrolimus. J am PLANTO. MMXIX: XIX: 2944-2948. View abstracto.
43. Laux LC, Bebin affectibus animi, Checketts D, et al. Long-term salute et efficacitati treatment cannabidiol in pueris et adultis cum Levinius-Gastaut syndrome, aut repugnans Dravet syndrome: Expanded obvius progressio praecessi. Res comitialibus. MMXIX, CLIV: 13-20. View abstracto.
44. Knaub K, T Sartorius, Dharsono T, Wacker R: Karl M, C. A Self-Schön Emulsifying medicamentis Delivery System (SEDDS) Ex Technology Improving Oralis Biodisponibilidad de Silo VESIsorb Cannabidiol in sanus subditis. Molecules. MMXIX; XXIV. pii: E2967. View abstracto.
45. A. Klotz, Hirsch M, Heers M, Schulze Bonhage-A, J. Jacobs Effectus cannabidiol super plasma brivaracetam levels. Epilepsia. MMXIX: LX: e74-e77. View abstracto.
46. Heussler H, J Cohen, Silove N; et al. A tempus 1/2, aperto-titulus taxationem salutem, tolerability, efficientia transdermal cannabidiol (ZYN002) treatment pro fragilibus pediatric X syndrome. J Neurodev Disord. MMXIX: XI: XVI. View abstracto.
47. Toro D, H Cook, Ortori C, D Barrett, Lund JN O'Sullivan autem. Inflammatio praeveni et effecerunt Palmitoylethanolamide Cannabidiol Hyperpermeability Vivo autem in humana Viscera In vitro A randomized, placebo-sobrie, sobrie iudicium duplex caecus. Viscus Inflamm disp. MMXIX: XXV: 1006-1018. View abstracto.
48. Birnbaum AK, Karanam A Marino se, et al. Farmacocinética cibis effectum in de praefractos cannabidiol oris Capsulae in adulta cum aegris comitialibus. Epilepsia. Aug MMXIX: LX: 1586-1592. View abstracto.
49. Arkell TR Lintzeris N, Kevin R., et al. Cannabidiol (CBD), non contentus in vanescuit cannabis ne tetrahydrocannabinol (THC) -induced incom fugandum et completivum cognitionis. Psychopharmacology (Berl.) MMXIX, CCXXXVI, 2713-2724. View abstracto.
50. LL Anderson Manus Absalom, NL, & SV Abelev, et al. Coadministered cannabidiol et Clobazam: utrumque enim quod Preclinical pharmacodynamic et pharmacokinetic interactions. Epilepsia. 2019. View abstracto.
51. Productum notitia ad Marinol. AbbVie. Septentrionalis Chicago, IL 60064. August MMXVII.Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018651s029lbl.pdf.
52. Epidiolex (cannabidiol) prescribing notitia. Greenwich Biosciences, Inc., Diego, CA, 2019. Available at: https://www.epidiolex.com/sites/default/files/EPIDIOLEX_Full_Prescribing_Information.pdf (accessed 5/9/2019)
53. Dicitur ex FDA legatus Scotus Gottlieb M.D. in subscriptionem de Cultura Latina Act scriptor propellente et cannabis et cannabis uber postulo temperatione propriae suis Revolutionibus componit. US Cibus et medicamentis Administration Web site. Available at: https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-signing-agriculture-improvement-act-and-agencys. (Accessed May VII, MMXIX).
54. Cultura Latina Act S. (X)CXIII: 115th Cong. sive S. (XII)DCXIX: 115th Cong. .
55. Effectus medicamentis Administration, de Department Iustitiae. Schedule of dispensata substantiis: Placement in V Morbi rhoncus ex FDA-probatissimorum quaedam medicinae continens Cannabidiol; Mutare correspondentes permittite, ut tincidunt. Ultima ordinis. H, in Regist. Sep MMXVIII XXVIII, LXXXIII, 48950-3. View abstracto.
56. Schoedel duae KA, Szeto Ego Setnik B, et al. Tandem abutere cannabidiol aestimationem habet potentiale (CBD) in ludicras polydrug users: A randomized, geminus-cæcus, sobrie iudicium. Comitialibus Behav. Nov MMXVIII: LXXXVIII: 162-171. doi: 10.1016 / j.yebeh.2018.07.027. Oct Epub MMXVIII 2. View abstracto.
57. Devinsky Domine, Verducci C, Thiele EA, crit et al. Aperta-titulus usum highly CBD purificetur (Epidiolex®) in cum aegris diminutum CDKL5 Aicardi et inordinatio, Dup15q et Doose syndromes. Comitialibus Behav. Sep MMXVIII: LXXXVI, 131-137. Iul 11 ​​Epub MMXVIII View abstracto.
58. Szaflarski JP, Bebin affectibus animi, messorem G, J DeWolfe, et al. Cannabidiol improves frequency et severitatem invasiones et reduces adversa certe per aperta-titulus addendi studiis in futurum. Comitialibus Behav. Oct MMXVIII: LXXXVII, 131-136. Aug 9 Epub MMXVIII View abstracto.
59. Linares IM, Zuardi Alpha Omega, LC spacium a'ris, et al. U informibus-dose reciproce responsum Cannabidiol praesentes esse curvam Tautochronam in simulatis forenses test. J Braz Psychiatry. Jan-Feb MMXIX: XLI: 9-14. Oct 11 Epub MMXVIII View abstracto.
60. Poklis, s Mulder, HA: Pax MR. Quod idem de cannabimimetic inopinatum, 5F, ADB, dextromethorphan in e-commercium available cannabidiol liquorum. Forensic Sci Int. Ian MMXIX: CCXCIV: E25, E27. Epub MMXVIII Nov View 1. abstracto.
61. Kurd YL, Spriggs S: Alishayev J; et al. Derivari-impetravisset, Reductio ad concupiscendum, sit et de Cannabidiol maeror in medicamentis abstinens a cibis, et fideles singuli Heroin inordinatio usus: placebo-sobrie iudicium Randomized A duplex caecus. J am Psychiatry. MMXIX: appiajp201918101191. View abstracto.
62. Ea Thiele Marsh ED Gallico JA, et al. Cum Levinius-Gastaut syndrome consociata cum aegris in Cannabidiol rapinae (GWPCARE4): a randomized, duplex caecus, placebo-sobrie iudicium tempus III. SCALPELLUM. Mar MMXVIII XVII: CCCXCI, 1085-1096. View abstracto.
63. Devinsky Domine, Patel AD, Cornelius Cross; et al. Levinius-Gastaut invasiones in effectu Cannabidiol Iacta super syndrome. N best J Med. May XVII MMXVIII: CCCLXXVIII, 1888-1897. View abstracto.
64. Pavlovic R: Nenna G, Calvi L, et al. Qualis est Lineamenta "olea Cannabidiol ': cannabinoids jam satis est-oxidatio, et terpene fingerprint De stabilitate in Europae Apparatum commercium available. Molecules. XX Maii MMXVIII: XXIII. pii: E1230. View abstracto.
65. Jannasch F, Kruger J, Schulze MB. Typus II diabete et puritate alimentorum exemplaria: Systematicam Review Texts and Studies FUTURUS Meta-analysis. J Nutr. Iun MMXVII: CXLVII: 1174-1182. View abstracto.
66. T Nepthalim: Mechulam R, Mariis conferendum A, et al. Sed effective, non tutum est in low-dose curatio de cannabidiol Morbus Crohn: a randomized dispensata iudicio. De Dis Romanorum cap ed. Iun MMXVII: LXII, 1615-20. View abstracto.
67. Nabu tionales EH, Offermann ea, Sievers JW, relinquens Comi AM. Cannabidiol curatio praefracti quia lunaticus est in Sturye-Weber syndrome. Pediatr Neurol. Iun MMXVII; LXXI: 18-23.e2. View abstracto.
68. Yeshurun ​​M, Shpilberg Domine, Herscovici C, et al. Cannabidiol inminentia prohiberent, exercitum versus inserere, allogeneic post morbo hematopoietic-cell transplantatio, eventus a studio tempus II. Gen sanguis medulla PLANTO. Oct MMXV: XXI: 1770-5. View abstracto.
69. Galfredus AL, SF Polledro Bruno PL Thiele ea. Pharmacum-medicamento Clobazam actionem mutuam in filios et cannabidiol refractariis comitialibus. Epilepsia. Aug MMXV; LVI, 1246-51. View abstracto.
70. Devinsky Domine, Marsh E, D Friedman, et la. Curatio in patientibus comitialibus Cannabidiol repugnans, est aperta-titulus interventional iudicii. SCALPELLUM Neurol. Mar MMXVI, XV, 270-8. View abstracto.
71. (XCVII)XXI Jadoon duae KA, SH Ratcliffus, Barrett DA; et al. Salus et virtus et cannabidiol tetrahydrocannabivarin in patientibus typus II diabete, in glycemic et lipidorum parametris: a randomized, duplex caecus, placebo-sobrie: parallel gubernatori studium coetus. Diabete Carbonicum. Oct MMXVI, XXXIX, 1777-86. View abstracto.
72. Gofshteyn Vivaldi, A Wilfong, Devinsky Domine, et al. Cannabidiol pro potential treatment pro lingua sed torpet infectio-related morbo comitiali syndrome (IGNES) in acuti et inveterata uti potest conditionibus. J: Fili Neurol. Ian MMXVII: XXXII: 35-40. View abstracto.
73. J. Gerardus Hess: A. Moody constabat, Galfridus AL, et al. Ut ad medicamento curatio nova Cannabidiol comitiali morbo-repugnant tuberosa in universa duros nequeunt movere lumbos. Epilepsia. Oct MMXVI, LVII, 1617-24.View abstracto.
74. Gasto TE, Bebin affectibus animi, GR messorem, Liu Y, Szaflarski JP; Program UAB CBD. Et interactiones inter cannabidiol antiepileptic communiter medicinae. Epilepsia. Sep MMXVII: LVIII: 1586-92. View abstracto.
75. Devinsky Domine, Cornelius Cross: Laux L, et al. Nam iudicium ex cannabidiol medicamento repugnant invasiones in Syndrome Dravet. N best J Med. MMXVII XXV Maii, CCCLXXVI, 2011-2020. View abstracto.
76. Bonn-Miller MO Loflin MJE, Thoma BF quandam addidimus, Marcu JP, Hyke T, R. Vandrey Labeling accurate collecta cannabidiol vendidit online. Nov JAMA MMXVII, CCCXVIII, 1708-9. View abstracto.
77. Malfait AM, Gallily R: Sumariwalla patrem, et al. In non-psychotropica, cannabis anti-oris constitutum est cannabidiol therapeutic in cuidam arthritico-effecerunt musculus collagen arthritis. Kessinger Publishing Acad Sci Phil USA MM: XCVII: 9561-6. View abstracto.
78. Formukong ea, Evans AT, J. Müller. Anti-inflammatione analgesic et L. Cannabis sativa constituitur ex actione Inflammatio MCMLXXXVIII, XII, 361-71. View abstracto.
79. Valvassori S. Elíam G, B Petrus de Souza Attaiide, et al. Effectus oxidative accentus adductus est, amphetamine cannabidiol in generatione animalis exemplar quod inferebant. J Psychopharmacol MMXI: XXV: 274-80. View abstracto.
80. Esposito G, Scuderi C, C Savani, et al. In vivo Cannabidiol hebetat et beta amyloideo 1beta IL-inos suppresso neuroinflammation adduci possunt. J Pharmacol MMVII, CLI, 1272-9. View abstracto.
81. Esposito G, D De Filippis, Maiuri MC, et al. Cannabidiol inhibits inducible nitric cadmiae synthase et nitric cadmiae productio dapibus expressio in beta-eliciebatur amyloideae PC12 neurons in p38-map et NF kappaB discoideum implicationem. Litterae apostolicae Neurosci MMVI, CCCXCIX (1-2), 91-5. View abstracto.
82. Iuvone T, G Esposito, De Filippis D, et al. Cannabidiol: medicamento in neurodegenerative perturbationes novo promissum est? Potis Neurosci Ibi MMIX, XV, 65-75. View abstracto.
83. Bisogno T, Y graeci Di Marzo endocannabinoid ratio in partes per Alzheimer scriptor morbus: et facta hypotheses statuendo. De Curr pharm MMVIII, XIV, 2299-3305. View abstracto.
84. Zuardi ne. Cannabidiol: ab ullo conatu sedentes in Cannabinoid ad medicamento actio lato spectro. Bras Psiquiatr MMVIII Psalm: XXX: 271-80. View abstracto.
85. Izzo A, F Borelli, R Capasso, et al. Non psychotropic plant cannabinoids: Curationis novum occasiones et ex antiquis herba. Sci trends Pharmacol MMIX: XXX: 515-27. View abstracto.
86. Booz Modus vacandi beneficiorum. Cannabidiol emergens ac medicinales belli oxidative accentus minuendo suasit impulsum ad inflammationes moveat. Liberum radic Mol Biol MMXI, LI, 1054-61. View abstracto.
87. Pickens JT. Cannabis actionem respectu delta' leniendo, et trans tetrahydrocannabinol cannabidiol contentus. J Pharmacol MCMLXXXI; LXXII, 649-56. View abstracto.
88. Monti | JM. Hypnoticlike in effectis cannabidiol rat. Psychopharmacology (Berl) MCMLXXVII, LV, 263-5. View abstracto.
89. Karler R, SA Turkanis. Subacutis Cannabinoid curatio: In excitability anticonvulsant actio et recessum ab mures inclusi essent. J Pharmacol MCMLXXX: LXVIII: 479-84. View abstracto.
90. Karler R: Cely W, Turkanis SA. Operatio autem anticonvulsant cannabidiol cannabinol et. Sci MCMLXXIII: XIII: 1527-31. View abstracto.
91. Consroe PF Wokin iniuria. Anticonvulsivante commercium ethosuximide in cannabidiol et mures inclusi essent. J pharm Pharmacol MCMLXXVII: XXIX: 500-1. View abstracto.
92. Consroe P: Wolkin A. Cannabidiol antiepilpetic-medicamento interactiones in similitudinem rapinae et huiusmodi sentiuntur in adductus mures inclusi essent. Ibi MCMLXXVII J Pharmacol Exp, CCI, 26-32. View abstracto.
93. Carlini EA compositâ, Leite R, M Tannhauser, Berardi c. Littera: Cannabidiol et mures inclusi essent et mures aureos Cannabis sativa extract protegat adversus insanos comprimere agentibus. J pharm Pharmacol MCMLXXIII: XXV: 664-5. View abstracto.
94. C. Cryan: Marci Aurelii A: I. Lucki Perpendendis actio in antidepressant talpas: et crevit necessitatibus profuturas. Sci trends Pharmacol MMII: XXIII: 238-45. View abstracto.
95. El-Alfy AT, Ivey K, K Robinson; et al. Antidepressant effectus, sicut ex delta9, tetrahydrocannabinol cannabinoids et alia separatim ab L. Cannabis sativa Pharmacol Biol Behav MMX, XCV, 434-42. View abstracto.
96. Resstel reclae LB, Tavares RF, SF Lisboa, et al. V-sunt implicari in cannabidiol HT1A receptores, quo humanarum et cardiovascular adductus ADTENUATIO in respondeo ut acuti accentus mures inclusi essent. J Pharmacol MMIX, CLVI, 181-8. View abstracto.
97. Granjeiro affectibus animi, Gomes IV, Guimaraes habitum et al. De administratione autem effectus intracisternal cannabidiol in cardiovascular et modus se modeste videri respondeo ut acuti accentus. Pharmacol Biol Behav MMXI, XCIX, 743-8. View abstracto.
98. Murillo Rodriguez-E: Aldaco McMillan, D, M Palomero, Rivero, et al. Cannabidiol: Cannabis sativa ex ipsius constitutionis est pars, modulatur dormiat mures inclusi essent. Litterae apostolicae FEBS MMVI, DLXXX, 4337-45. View abstracto.
99. De Filippis D, G Esposito, Cirillo C, et al. Cannabidiol reduces intestinorum inflammatio neuroimmune axis per imperium. PLoS unus MMXI: VI: e28159. View abstracto.
100. Bhattacharyya S, P Fusar, Poli, Borgwardt S, et al. Mediotemporal in similitudinem modulatis et ventrostriatal munus ab hominibus, Delta9 tetrahydrocannabinol: nam effectus a neural ex doctrina et ex Cannabis sativa in PSYCHOSIS. Genesis arcus Psychiatry MMIX: LXVI: 442-51. View abstracto.
101. Dal ton S, R Martz, Lemberger L, et al. Gamma-IX-de movere ex cannabidiol tetrahydrocannabinol effectus. Clin Pharmacol Ibi MCMLXXVI: XIX: 300-9. View abstracto.
102. Guimaraes VM, Zuardi G., De conflatus est Bel contritus EA compositâ, Guimaraes habitum est. Addit significatio nucleum Cannabidiol Fos accumbens dorsalibus non striatum. Sci MMIV, LXXV, 633-8. View abstracto.
103. Moreira FA contentum, Guimaraes habitum est. Deiciunt Cannabidiol hyperlocomotion inductus psychomimetic medicamina mus. J Pharmacol MMV, DXII (2-3): 199-205. View abstracto.
104. Le Long: Chesworth R, Huang ipsa XF, et al. A similitudine morum Delta9-acuti et inveterata apud tetrahydrocannabinol et cannabidiol C57BL / 6JArc mures inclusi essent. Int J Neuropsychopharmacol MMX, XIII, 861-76. View abstracto.
105. Alpha Omega Zuardi, Rodriguez JA Cunha JM. Ex animali exemplo Predictive antipsychotic cannabidiol effectus actionis. Psychopharmacology (Berl) MCMXCI: CIV: 260-4. View abstracto.
106. Malone DT, Jongejan D Sociorum Treuttel vivit. Cannabidiol vel adversas imminutas conversationis causa produci humilis-dose tetrahydrocannabinol Graecum In mures inclusi essent. Pharmacol Biol Behav MMIX, XCIII: 91-6. View abstracto.
107. Schubart CD, Sommer applicatae IE, Fusar Lætatusque P, et al. Cannabidiol pro potential treatment pro PSYCHOSIS. Eur Neuropsychopharmacol MMXIV, XXIV, 51-64. View abstracto.
108. Camposinae in Arcanis Caelestibus, Moreira FA contentum, Gomes IV, et al. Multa et magna machinationes involved in spectro perturbationes mentis in cannabidiol therapeutica potentiale. Philos trans R Soc Lond Gen Sci MMXII B, CCCLXVII, 3364-78. View abstracto.
109. Lætatusque Fusar-P: P Allen, Bhattacharyya S, et al. Delta Locum IX-in processus motus effective per similitudinem modulatis connectivity tetrahydrocannabinol et cannabidiol. Int J Neuropsychopharmacol MMX, XIII, 421-32. View abstracto.
110. Casarotto PC, Gomes IV, Resstel reclae LB, Guimaraes habitum est. Cannabidiol inhibitory effectum in sepulchro maiorum mores marmora: efficiendum attinet, CB1 receptoribus. Behav Pharmacol MMX: XXI: 353-8. View abstracto.
111. Uribe Alba-A, A Francisco, Castiblanco Urbina-MA, et al. Innata est effectus timoris aversive anti- cannabidiol effecerunt mores exemplum terroris ortum ab ethological anguis impetum ex feris praeda nobis exemplar Epicrates cenchria Crassus conuenirent. Neuropsychopharmacology MMXII: XXXVII: 412-21. View abstracto.
112. Camposinae in Arcanis Caelestibus, Guimaraes habitum est. Activation de 5HT1A receptores, in mediis quam de cannabidiol anxiolytic effectus PTSD in exemplum. Behav Pharmacol MMIX: XX: S54.
113. Resstel reclae LB, Joca SR, Moreira FA contentum, et al. Valium et effectus in morum et cardiovasculares cannabidiol responsa inductus mures Contextual conditionata metus. Res apparet ingenium Behav MMVI, CLXXII, 294-8. View abstracto.
114. Moreira FA contentum, Aguiar DC, dictum est Guimaraes. Sicut effectus a cannabidiol anxiolytic-rat in conflictu Vogel test. Prag Neuropsychopharmacol Gen Psychiatry MMVI, XXX, 1466-71. View abstracto.
115. Onaivi ES, Mr Viridis, Martin rectae BR. Pharmacological elevatus est in plus respectu ad cannabinoids error. Ibi MCMXC J Pharmacol Exp, CCLIII, 1002-9. View abstracto.
116. Guimaraes parte Chairetti TM, Graeff FG Zuardi ne. Antianxiety cannabidiol effectus est in plus, elevatus est error. Psychopharmacology (Berl) MCMXC, C, 558-9. View abstracto.
117. Magen sum Abraham, Y, Z Ackerman, et al. Cannabidiol ameliorates motricium impairments in cognitiva, et quinque mures aureos et duct ligation. J Hepatol MMIX: LI: 528-34. View abstracto.
118. Rajesh M: P Mukhopadhyay, Batkai S, et al. Praesent cardiac Cannabidiol de dupla sesquitertia, oxidative accentus, fibrosis, et inflammatione et cell mortis diabetic cardiomyopathy signalling tractuum. J AM Coll Cardiol MMX, LVI, 2115-25. View abstracto.
119. El-Remessy AB, A Mars, Ola S, et al. Operatio pede placerat Glutamine synthetase neurons conservando Cannabidiol tuetur. Vis mol MMX; XVI, 1487-95. View abstracto.
120. El-Remessy AB, Shabrawey Al-M, N Mars, et al. Neuroprotective et sanguis-pede-obice effectus, servatis de experimentum in cannabidiol diabete. J am Pathol MMVI, CLXVIII, 235-44. View abstracto.
121. Rajesh M: P Mukhopadhyay, Batkai S, et al. Cannabidiol de dupla sesquitertia princeps GLYCOSA responsio-inflammatione et cell inducit endothelial obice disrumpatur. Circ Multiple Cordis J am physiol physiol MMVII, CCXCIII: H610-H619. View abstracto.
122. Kouacs C, M Jedrzejewski, Thomas L, Frey WH. Cannabinoid-mediata neuropathic similitudinem modulatis et doloris cumulum microglial per exemplum de type I musculus dolor neuropathic Diabetic periphericis. Dolor MMX mol: VI: XVI. View abstracto.
123. Aviello G, Romano B, F Borelli, et al. Chemopreventive effectus est non-psychotropic phytocannabinoid cannabidiol experimentalem ex colonia cancer. J Mol Biol (Berl) MMXII: XC: 925-34. View abstracto.
124. Lee CY, Wey SP, MH Liao, et al. A comparativo ad cannabidiol studio adductus-el-IV thymoma et apoptosis in thymocytes musculus cellulis. Int Immunopharmacol MMVIII, VIII, 732-40. View abstracto.
125. Massi P, M Valenti, Vaccani A, et al. V-Triticum aestivum et anandamide hydrolase (FAAH) antitumor operatio est medium ad cannabidiol, a non-psychotropica Cannabinoid. J Biol MMVIII: CIV: 1091-100. View abstracto.
126. Valenti M, Massi P: D Bolognini, et al. Cannabidiol, a non-cell glioma psychotropica Cannabinoid humanis compositis inhibits et invasiveness. 34th Conventum Societatis Italicae de Materia Medica MMIX.
127. Turribus, S, M Lorente, Rodriguez-F Fornes, et al. A combined Preclinical Lorem ex in cannabinoids et temozolomide glioma. Ibi MMXI mol Cancri: X: 90-103. View abstracto.
128. Quod Jacobsson, Rongard E, M Stridh, et al. Serum-effectus dependens ab tamoxifen et cannabinoids C6 glioma in cellam viability. Biol Pharmacol MM; LX, 1807-13. View abstracto.
129. A Shrivastava, Kuzontkoski PM Groopman Ioram, Prasad A. Cannabidiol inducit programmed mors in cellula pectus cancer cellulis per crucem-Disputatio coordinare inter autophagy et apoptosis. Ibi MMXI mol Cancri: X: 1161-72. View abstracto.
130. McAllister D, R Murase, Christiane RT, et al. Tractuum in media effectis cannabidiol reductionem pectus cancer cellam proliferation, tumultus, et metastasis. Pectus Cancer Res MMXI tracta: CXXIX, 37-47. View abstracto.
131. McAllister SD Christiano RT, Horowitz MP; et al. In se novi Cannabidiol inhibitor-I Id est in gene expressio iras pectus cancer cellulis. Ibi mol Cancri MMVII, VI, 2921-7. View abstracto.
132. A Ligresti, sicut Moriello, Starowicz K, et al. Antitumor operatio plantae cannabinoids cum emphasis super effectus in humanum in pectus cannabidiol carcinoma. Ibi J Pharmacol Exp MMVI, CCCXVIII, 1375-87. View abstracto.
133. Massi P, M Solinas, Cinquina V, Parolaro D. Cannabidiol anticancer pro potential medicamento. J Clin Pharmacol MMXIII, LXXV, 303-12. View abstracto.
134. Schubart CD, Sommer III naciones, WA Gastel, et al. Cannabis magna cannabidiol contentus est consociata cum paucioribus psychotici recepit. Res Schizophr MMXI, CXXX (1-3), 216-21. View abstracto.
135. A Englund: Cicero PD, Nottage J; et al. The-dependent hippocampal inhibits Cannabidiol signa memoria indigestionem paranoid elicitur. J Psychopharmacol MMXIII, XXVII, 19-27. View abstracto.
136. Devinsky Domine, Unio MR Cross S, et al. Cannabidiol: pharmacologicae et potentiale curationis neuropsychiatric perturbationes partes morbus caducus et alia. Epilepsia MMXIV, LV, 791-802. View abstracto.
137. Serpell MG, Notcutt W, Collin C. Sativex diu terminus usum: an iudicium in aegris cum aperto-titulus spasticity ob multiplicem lumbos. J Neurol MMXIII: CCLX, 285-95. View abstracto.
138. W Notcutt, Langford R: Valerius P, et al. A placebo-sobrie, coetus parallel, randomized recessum ab ordine rerum studium cum multa indicia ex spasticity qui duros nequeunt movere lumbos accepto longa-term Sativex (nabiximols). Mult Scler MMXII: XVIII: 219-28. View abstracto.
139. Caesar CM, Dasgupta R: Dal ton, et al. An aperta-titulus pro collecta studio fundatur CANNABUS, in vesica dysfuntion provectus multa duros nequeunt movere lumbos. Mult Scler MMIV, X, 425-33. View abstracto.
140. Kavia RB: De Ridder D, CS m Constantinescu, et al. Et facies iudicium a randomized dispensata est Sativex detrusor overactivity in multiple lumbos. Mult Scler MMX; XVI, 1349-59. View abstracto.
141. Wade DT, Makela PM Domus S, et al. Long-term treatment fundatur in usu et cannabis, spasticity et alia symptomata in multiple lumbos. Mult Scler MMVI, XII, 639-45. View abstracto.
142. A Novotna, et Mares J, Ratcliffus S, et al. A randomized, duplex caecus, placebo-sobrie, coetus parallel-umque studio, consilio nabiximols * (Sativex) addendi ut in Lorem et in rebus versatur de causa per plures durum spasticity duros nequeunt movere lumbos. J Neurol MMXI, XVIII, 1122-31. View abstracto.
143. Overview. Pharma VUL Web site.Available at: http://www.gwpharm.com/about-us-overview.aspx. Accessed, Maii XXXI, MMXV.
144. Cannabidiol nunc ostendo sursum in dietary supplements. Naturalis conficiendi medicamenta Web site. https://naturalmedicines.therapeuticresearch.com/news/news-items/2015/march/cannabidiol-now-showing-up-in-dietary-supplements.aspx. (Accessed Maii XXXI, MMXV).
145. Alpha Omega Zuardi, Cosme, Magistrum Graeff FG Guimaraes habitum est. Est effectus in humana experimentum cannabidiol ipsapirone et anxietatem. J Psychopharmacol MCMXCIII: VII (Suppl I), 82-8. View abstracto.
146. Leighty ex EG, eft AF Fentiman Jr Foltz RL. Diu retinuit, tenuissimum, et delta9- delta8 tetrahydrocannabinols identified exceptum audiuerunt, a coniugatis pingue acidum. Res Res viaticum Pathol Pharmacol MCMLXXVI, XIV, 13-28. View abstracto.
147. Samara E, M Bialer, R. Mechoulam Farmacocinética de cannabidiol in canibus. Metab medicamento Dispos MCMLXXXVIII: XVI: 469-72. View abstracto.
148. Consroe P, R Sandyk, snider SR. Pittacium iudicium de aperto cannabidiol in dystonic motus perturbationes. Int J Neurosci MCMLXXXVI: XXX: 277-82. View abstracto.
149. Crippa JA Derenusson GN, VALENTIN TB, et al. Neural ex effectis anxiolytic cannabidiol (CBD) in socialis generativus anxietas inordinatio, aliumque belli fama. J Psychopharmacol MMXI: XXV: 121-30. View abstracto.
150. Bornheim aequales, Everhart ET J Li, Correia MA. Cannabidiol respectu ad inactivation Cytochrome P450-mediatae. Biol Pharmacol MCMXCIII: XLV: 1323-31. View abstracto.
151. Song: Harvey. Lolium multiflorum; distribution atque Biotransformación de cannabinoids. Medical Marijuana et. MCMXCIX, 91-103.
152. Yamaori S: Ebisawa J, Okushima ego, et al. Per inhibitionis de homine ac Potentissimam Cytochrome P450 Isoforms cannabidiol 3A, phenolic hydroxyl partes in coetibus resorcinol medietatem. Sci MMXI, LXXXVIII (15-16) 730-6. View abstracto.
153. Yamaori S: Okamoto ego, Yamamoto I, C. Watanabe Cannabidiol, phytocannabinoid Maior autem: potens est enim precursor atypical CYP2D6. Metab medicamento Dispos MMXI, XXXIX, 2049-56. View abstracto.
154. Yamaori S: Maeda C, Yamamoto I, inhibitionis de homine Watanabe C. differentialium Cytochrome P450 a 2A6 et major phytocannabinoids 2B6. Osteogenesis Toxicol MMXI: XXIX: 117-24.
155. Yamaori S, M Kushihara, Yamamoto I, K Fungi Watanabe Maior de phytocannabinoids, et cannabidiol cannabinol, ut electionem selectivam, Mus potens inhibitors humano CYP1 ipsum. Biol Pharmacol MMX, LXXIX, 1691-8. View abstracto.
156. Alpha Omega Zuardi, Crippa JA Hallak Ioram, et al. Cannabidiol enim curatio de PSYCHOSIS in Parkinson scriptor morbus. J Psychopharmacol MMIX: XXIII: 979-83. View abstracto.
157. Morgan CJ Caesaris, A. Das, Joye A, et al. Cannabidiol reduces cigarette consummatio in tobacco smokers: praevia Inventiones. Dior Behav MMXIII: XXXVIII: 2433-6. View abstracto.
158. Pertwee KG. De diverse CB1 CB2 et receptor plant cannabinoids pharmacologicae de tribus: delta9, tetrahydrocannabinol, et cannabidiol delat9, tetrahydrocannabivarin. J Pharmacol MMVIII, CLIII, 199-215. View abstracto.
159. Leweke FM, Kranaster E, F Pahlisch, et al. Quod efficacia curatio cannabidiol in SCHIZOPHRENIA - approach translational est. MMXI Schizophr tauri: XXXVII (Suppl I) CCCXIII.
160. Leweke FM, Piomelli D, F Pahlisch, et al. Cannabidiol Enhances anandamide signalling psychotici et lenit indicia SCHIZOPHRENIA. Lesbia Psychiatry MMXII, II: e94. View abstracto.
161. Carroll CB, & PG Bain, Teare L, et al. Cannabis dyskinesia in Parkinson in morbo: a randomized, duplex caecus studio crossover. Neurology MMIV, LXIII: 1245-50. View abstracto.
162. Bergamaschi MM Queiroz RH, Chagas MH, et al. Reduces in anxietatem Cannabidiol adductus curatio, in simplicitate simulata forenses socialis phobia aegris. Neuropsychopharmacology MMXI, XXXVI, 1219-26. View abstracto.
163. Alpha Omega Zuardi, Crippa JA Hallak Ioram, et al. Cannabidiol a Cannabis sativa constitutionis est pars, ut in medicamento antipsychotic. Braz J Mol Biol Res MMVI, XXXIX, 421-9. View abstracto.
164. Yadav V; jr Bever C, Ortelius J; et al. Quod fundatur ratio,-summary of: complementary quod alternative medicina et in multiple lumbos, ratio, progressus fama de American Academy of Subcommittee de Neurology. Neurology. MMXIV, LXXXII, 1083-92. View abstracto.
165. Trembly B, Sherman M. duplex caecus studio orci cannabidiol anticonvulsant quasi secundarium. '90 Marijuana Congressus Internationalis Cannabis et cannabinoids MCMXC, II, V.
166. Srivastava, M. D.: Srivastava: I. B. et Brouhard, et cannabidiol tetrahydrocannabinol Delta9 B. productio per altaris cytokine humanae immune cellulis. Immunopharmacology MCMXCVIII: XL: 179-185. View abstracto.
167. Cunha, JM, Carlini, EA contingct, spacium a'ris, AE, Diego, Domine, Pimentel, C., Gagliardi, R., Sanvito, aquâ discus, Lander tuarum N. et Mechoulam, R. Longos administrandae cannabidiol est aegris sana volunteers et lunaticos . Materia Medica MCMLXXX: XXI: 175-185. View abstracto.
168. Carlini EA compositâ, Cunha JM. Et antiepileptic cannabidiol de hypnotic effectus. Clin Pharmacol J MCMLXXXI, XXI (Suppl 8-9) 27S-417S. View abstracto.
169. Zuardi, A. W., Shirakawa, I., Finkelfarb, E., and Karniol: I. G. cannabidiol in anxietatem et alia actio effectus produci gamma-IX THC normalis in subiecto. Psychopharmacology (Berl) MCMLXXXII: LXXVI: 245-250. View abstracto.
170. Ames, M. R. Et Cridland: S. Anticonvulsivante cannabidiol effectus est. S.Afr.Med.J. 1-4-1986, LXIX: XIV. View abstracto.
171. Ohlsson, A., Lindgren, J. E. Jeps, S., Agurell, S., Gillespie, H. et Hollister, L. E Album-dose of deuterium equilibrium, intitulatum post fumigans cannabidiol apud hominem et intravenous administratione. Biomed.Environ Spectrom Missam. MCMLXXXVI, XIII, 77-83. View abstracto.
172. Wade, Titus D., Collin, C., Stott: C. et Duncombe, C. Meta-analysis de virtus et salus Sativex (nabiximols), et plures ex populo spasticity apud duros nequeunt movere lumbos. Mult.Scler. MMX; XVI, 707-714. View abstracto.
173. Collin, C., Ehler, E., Waberzinek, G.: Alsindi, Z., Tacitus, Publius, Powell, K, Notcutt, W., O'Leary, C., Ratcliffo, S., Novakova ego ., Zapletalova, O., Pikova, J. et Ambler, Z., duplex caecus, randomized, placebo-sobrie, studio Sativex parallel-coetus, in subiectos multa signa spasticity ex duros nequeunt movere lumbos. Neurol.Res. MMX: XXXII: 451-459. View abstracto.
174. Crippa, J. A., Zuardi, A. W., Martin-Paulo, R., Bhattacharyya, S., Atakan, Z., McGuire, P., and Fusar, Poli, p Cannabis anxietatem et critice review de testimonio. Hum.Psychopharmacol. MMIX: XXIV: 515-523. View abstracto.
175. Consroe, P., Vel, J., Allender, J., Snider, S. Stern L., Sandyk, R., Kennedy, K., et Schram, K Gramineae iudicium de cannabidiol orci in Cambridge University scriptor morbus. Pharmacol Biochem.Behav. MCMXCI: XL: 701-708. View abstracto.
176. Harvey, D. J., Samara, E., and Mechoulam, R. Disputatio humorum in cannabidiol canis, rat et hominibus. Pharmacol Biochem.Behav. MCMXCI: XL: 523-532. View abstracto.
177. Collin, C.: Tacitus, Publius, Mutiboko, I. C. et Ratcliffo, S. randomized dispensata iudicio, cannabis fundatur in medicina per plures spasticity causa duros nequeunt movere lumbos. Eur.J.Neurol. MMVII, XIV, 290-296. View abstracto.
178. Massi, P., Vaccani, A., Bianchessi, S., & Costa, B., Macchi, P., and Parolaro, D. de non-activation et oxidative accentus psychotropica cannabidiol triggers caspase glioma in humana cellulis. Cell Mol.Life ed. MMVI: LXIII: 2057-2066. View abstracto.
179. Weiss, L., Zeira, M., Reich, S., in monte Obama Ipsum, M., Mechoulam, R., Slavin, S., et Gallily, R. Cannabidiol caput sic dimittit incidentiae de diabete in non-obesus diabetic mures inclusi essent. MMVI autoimmunity: XXXIX: 143-151. View abstracto.
180. Watzl, B., Scuderi, P., and mi Watson, R. R. Marijuana components stimulate periphericis humanum sanguinem supprimunt atramentum et gamma-interferon secretio mononuclear cellula in vitro interleukin alfa-I. Int J Immunopharmacol. MCMXCI, XIII, 1091-1097. View abstracto.
181. Consroe, P., Kennedy, K., et Schram, feodis praedictis E. et per capillarium imperat plasma cannabidiol Gas Angiospermae / ion spectroscopio post captionem massa summus dose oralis administrationis cotidie apud homines. Pharmacol Biochem.Behav. MCMXCI: XL: 517-522. View abstracto.
182. Barnes, p M. Sativex: tolerability et orci in curatio efficaciam de multa signa doloris neuropathic et duros nequeunt movere lumbos. Expert.Opin.Pharmacother. MMVI, VII, 607-615. View abstracto.
183. Wade, D. T. Makela, P., Venice, P., Domus, H. et Bateman C. Et cannabis, secundum medicinales effectus in propria vel communia symptoms in collecta habent multiplicem lumbos? Duplici A-caecorum randomized, placebo-sobrie studiis super CLX aegris. Mult.Scler. MMIV: X: 434-441. View abstracto.
184. Iuvone T. Esposito, G.: Esposito, R., Santamaria, R., De Rosa, M. et Izzo sicut supra dictum est cannabidiol neuroprotective effectus, est a non-pars psychotropica Cannabis sativa, amyloideae, adductus est beta- toxicity PC12 per cellulas. J Biol. MMIV: LXXXIX: 134-141. View abstracto.
185. Massi, P., Vaccani, A.: Ceruti, S., Colombo, A., Abbracchio, M., P., et Parolaro, D. antitumor cannabidiol effectis, a nonpsychoactive Cannabinoid in cellulam hominum glioma lineae. J Pharmacol Exp.Ther. MMIV: CCCVIII: 838-845. View abstracto.
186. Crippa, JA: Zuardi, A., Garrido constituto, GE, Wichert-Anæ L., Guarnieri, R., VALENTIN L., Marques, Azevedo, PM Hallak, Ioram, McGuire, PK, & Filho, G. effectus Busatto de cannabidiol (CBD) in regionali cerebri et effundatur sanguis. Neuropsychopharmacology MMIV: XXIX: 417-426. View abstracto.
187. Wade, Titus D., Robson, P., Domus, H., Makela P: fugeruntque Syri, quod pertinet, prima J. dispensata studiis ad determinare sive meliorem possunt collecta omnis herba cannabis implacabiles cernebam Neurogenic docebo. Clin.Rehabil. MMIII: XVII: 21-29. View abstracto.
188. Covington TR, et al. Historia Medicinae nonprescription. 11th ed. Washington, DC, American Pharmaceutical Association, MCMXCVI.

From Review - 12/18/2020